Seres Therapeutics Statistics
Seres Therapeutics (1S90) Stock Statistics & Valuation Metrics
Total Valuation
Seres Therapeutics has a market cap or net worth of EUR 14.33M. The enterprise value is EUR 51.68M.
- Market Cap
- EUR 14.33M
- Enterprise Value
- EUR 51.68M
Share Statistics
Seres Therapeutics has 10,195,031 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 10,195,031
- Owned by Insiders
- 1.42%
- Owned by Institutions
- 7.73%
Financial Efficiency
Seres Therapeutics’s return on equity (ROE) is 0.13 and return on invested capital (ROIC) is -72.70%.
- Return on Equity (ROE)
- 0.13
- Return on Assets (ROA)
- 0.04
- Return on Invested Capital (ROIC)
- -72.70%
- Return on Capital Employed (ROCE)
- -0.79
- Revenue Per Employee
- 11.95K
- Profits Per Employee
- 86.30K
- Employee Count
- 66
- Asset Turnover
- 0.01
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Seres Therapeutics is -0.30. Seres Therapeutics’s PEG ratio is -0.18.
- PE Ratio
- -0.30
- PS Ratio
- 7.20
- PB Ratio
- 0.70
- Price to FCF
- -0.24
- Price to Operating Cash Flow
- -0.23
- PEG Ratio
- -0.18
Income Statement
In the last 12 months, Seres Therapeutics had revenue of 789.00K and earned 5.70M in profits. Earnings per share was 0.64.
- Revenue
- 789.00K
- Gross Profit
- -3.34M
- Operating Income
- -93.97M
- Pretax Income
- 5.70M
- Net Income
- 5.70M
- EBITDA
- 9.83M
- Earnings Per Share (EPS)
- 0.64
Cash Flow
In the last 12 months, operating cash flow was -63.94M and capital expenditures -29,000, giving a free cash flow of -63.97M billion.
- Operating Cash Flow
- -63.94M
- Free Cash Flow
- -63.97M
- Free Cash Flow per Share
- -6.41
Dividends & Yields
Seres Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -418.31%
- Earnings Yield
- -313.58%
Stock Price Statistics
- Beta
- -2.35
- 52-Week Price Change
- -87.72%
- 50-Day Moving Average
- 2.92
- 200-Day Moving Average
- 5.55
- Relative Strength Index (RSI)
- 30.97
- Average Volume (3m)
- 237
Important Dates
Seres Therapeutics upcoming earnings date is Mar 02, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 04, 2026
- Next Earnings Date
- Mar 02, 2027
- Ex-Dividend Date
- ―
Financial Position
Seres Therapeutics as a current ratio of 2.56, with Debt / Equity ratio of 187.63%
- Current Ratio
- 2.56
- Quick Ratio
- 2.56
- Debt to Market Cap
- 0.08
- Net Debt to EBITDA
- 3.78
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Seres Therapeutics has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Seres Therapeutics EV to EBITDA ratio is -0.52, with an EV/FCF ratio of -0.52.
- EV to Sales
- 15.78
- EV to EBITDA
- -0.52
- EV to Free Cash Flow
- -0.52
- EV to Operating Cash Flow
- -0.52
Balance Sheet
Seres Therapeutics has EUR 17.53M in cash and marketable securities with EUR 35.77M in debt, giving a net cash position of -EUR 18.24M billion.
- Cash & Marketable Securities
- EUR 17.53M
- Total Debt
- EUR 35.77M
- Net Cash
- -EUR 18.24M
- Net Cash Per Share
- -EUR 1.79
- Tangible Book Value Per Share
- EUR 2.14
Margins
Gross margin is 49.51%, with operating margin of -3388.42%, and net profit margin of -2209.55%.
- Gross Margin
- 49.51%
- Operating Margin
- -3388.42%
- Pretax Margin
- -2209.55%
- Net Profit Margin
- -2209.55%
- EBITDA Margin
- -3015.62%
- EBIT Margin
- -3151.44%
Analyst Forecast
The average price target for Seres Therapeutics is EUR 15.22, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- EUR 15.22
- Price Target Upside
- 922.91% Upside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 2
- Revenue Growth Forecast
- 509.53%
- EPS Growth Forecast
- -720.57%
